RFP- Documenting the efficacy, safety, and acceptability of medication abortion up to 97 days Grant

The Society of Family Planning aims to document the efficacy, safety, and acceptability of medication abortion up to 97 days, addressing a critical gap in abortion care. With medication abortion comprising 63% of all abortions in the U.S. in 2023, this funding opportunity seeks to generate vital data beyond the FDA's 70-day approval, promoting evidence-informed and person-centered clinical practices for those needing abortion care later in pregnancy.

Purpose
Medication abortion is an effective and safe method of abortion care, and in 2023, it comprised 63% of all abortions in the formal US healthcare system. While the FDA has approved the use of mifepristone with misoprostol for medication abortion through 70 days of gestation, clinical guidance from national and international organizations affirms its effective and safe use beyond 70 days.
Recognizing that pregnant people may want or need medication abortion after 70 days, rigorous research on the efficacy, safety, and acceptability of medication abortion at different estimated gestational durations is crucial to advancing evidence-informed and person-centered clinical care. To this end, the Society of Family Planning is offering the Documenting the efficacy, safety, and acceptability of medication abortion up to 97 days funding opportunity. This funding opportunity aims to build upon the existing knowledge base by generating data that further advances evidence-informed and person-centered medication abortion care.